Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Steven Paul Insider Profile

18 Followers

Steven Paul, Director at Rapport Therapeutics, Inc., holds 555.02K shares in Rapport Therapeutics, Inc. (Ticker: RAPP), holds 863.03K shares in Seaport Therapeutics, Inc. (Ticker: SPTX), holds 0.00 shares in Karuna Therapeutics (Ticker: KRTX). Most recently, Steven Paul Bought ― shares of Rapport Therapeutics, Inc. on Oct 22, 2026 for an estimated value of $974.28K.

Steven Paul's Trading History

RAPPRapport Therapeutics, Inc.		Oct 22, 2026DirectorInformative Buy974.28K$13.90M
SPTXSeaport Therapeutics, Inc.		May 04, 2026DirectorUninformative Buy―$16.92M
KRTXKaruna Therapeutics		Mar 18, 2024―Uninformative Sell49.82M$0.00
SAGESAGE Therapeutics		Nov 30, 2022―Uninformative Buy190.80$5.15M
ALNYAlnylam Pharma		Apr 05, 2022DirectorUninformative Buy169.95K$165.00K
SIALSigma-Aldrich Corp		Nov 19, 2015―Uninformative Sell66.92K―
LLYEli Lilly & Co		Feb 03, 2010EVP, Science and TechnologyUninformative Buy610.79K$110.48M
VYGRVoyager Therapeutics		―Director――
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Steven Paul insider profile FAQ

What is the percentage of profitable transactions made by Steven Paul?
The percentage of profitable transactions made by Steven Paul is 71%.
What is the average return per transaction made by Steven Paul?
The average return per transaction made by Steven Paul is 102.90%.
What stocks does Steven Paul hold?
Steven Paul holds: RAPP, SAGE, VYGR, KRTX, SPTX, ALNY, SIAL, LLY stocks.
What was Steven Paul’s latest transaction?
Steven Paul’s latest transaction was an Informative Buy of $974.28K.
What was Steven Paul's most profitable transaction?
Steven Paul’s most profitable transaction was an Informative Buy of KRTX stock on July 1, 2019. The return on the trade was 406.90%.
What is Steven Paul's role in Rapport Therapeutics, Inc.?
Steven Paul's role in Rapport Therapeutics, Inc. is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.